Newly Developed Dual Topoisomerase Inhibitor P8-D6 is Highly Active in Ovarian Cancer
Inken Flörkemeier(Christian-Albrechts-Universität zu Kiel), Dirk Bauerschlag(Christian-Albrechts-Universität zu Kiel)
Cited by 1
Related Papers
ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids
|Cancers|2021|32
ADAM17 inhibition enhances platinum efficiency in ovarian cancer
|Oncotarget|2018|27
Untersuchungen des dualen Topoisomerase-Inhibitors P8-D6 für die Therapie gynäkologischer Tumore
|MACAU: Open Access Repository of Kiel University (University Library Kiel)|2021|0
Dual Topoisomerase Inhibitor Is Highly Potent and Improves Antitumor Response to Radiotherapy in Cervical Carcinoma
|International Journal of Molecular Sciences|2025|0